22:55 , May 11, 2018 |  BioCentury  |  Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May 8,...
01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global biopharma...
04:35 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

IdeS: Ph II discontinued

Hansa discontinued an open-label, U.K. Phase II trial evaluating a single IV dose of IdeS after preliminary data from 2 asymptomatic patients with acquired TTP showed a "non-favorable" risk-benefit profile. The company said that while...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

IdeS: Phase II started

Hansa began an open-label, U.K. Phase II trial to evaluate single doses of 0.25 and 0.5 mg/kg IV IdeS in up to 6 patients with acquired TTP and low ADAMTS13 activity who are asymptomatic. Hansa...
07:00 , Sep 10, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: ADAM metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13)

Hematology INDICATION: Thrombocytopenia In vitro studies suggest a modified form of ADAMTS13 could help treat thrombotic thrombocytopenic purpura (TTP). Autoantibodies from TTP patients inhibit ADAMTS13-mediated cleavage of von Willebrand factor (vWF) by an unknown mechanism. Structural analysis...
07:00 , Jul 13, 2015 |  BioCentury  |  Strategy

Baxalta's blueprint

Now that Baxalta Inc. has completed its spinout from Baxter International Inc., the newco's ambitious plan is to launch 20 new drugs, including line extensions, by 2020. The products, which come from a mix of...
08:00 , Feb 24, 2011 |  BC Innovations  |  Targets & Mechanisms

A NAC for TTP

U.S. and Canadian researchers have found that the generic drug N-acetylcysteine could be repurposed for use in thrombotic thrombocytopenic purpura, a rare hematological disorder for which cumbersome plasma exchange therapy has been the standard of...
07:00 , Aug 27, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact nformation Cardiovascular disease Ischemia; reperfusion injury ...
07:00 , Oct 20, 2008 |  BC Week In Review  |  Clinical News

ADAMTS13 regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for ADAMTS13 to treat thrombotic thrombocytopenic purpura ( TTP). Baxter licensed ex-Japanese rights to the disintegrin and metalloprotease protein,...
07:00 , Oct 22, 2007 |  BC Week In Review  |  Company News

Baxter, Chemo-Sero-Therapeutic Research Institute deal

The institute granted BAX an exclusive license to develop and commercialize recombinant ADAMTS13 worldwide, except in Japan, where the partners will co-commercialize the compound. The disintegrin and metalloprotease protein is in preclinical testing to...